How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/delapril-delapril-manidipine-fixed-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Delapril, Delapril-Manidipine Fixed combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Delapril, Delapril-Manidipine Fixed combination (Delapril, Delapril-Manidipine Fixed combination) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor / Calcium channel blocker combination. Area: Cardiovascular.

phase 3 ACE inhibitor / Calcium channel blocker combination ACE (angiotensin-converting enzyme) and L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Delapril, Delapril-Manidipine Fixed combination (Delapril, Delapril-Manidipine Fixed combination) — Mario Negri Institute for Pharmacological Research. Delapril is an ACE inhibitor that reduces blood pressure by blocking angiotensin II formation, combined with manidipine, a calcium channel blocker that causes vasodilation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Delapril, Delapril-Manidipine Fixed combination TARGET	Delapril, Delapril-Manidipine Fixed combination	Mario Negri Institute for Pharmacological Research	phase 3	ACE inhibitor / Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels
trandolapril/verapamil	trandolapril/verapamil	Abbott	marketed	ACE inhibitor / calcium channel blocker combination	Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor / Calcium channel blocker combination class)

Mario Negri Institute for Pharmacological Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Delapril, Delapril-Manidipine Fixed combination — Competitive Intelligence Brief. https://druglandscape.com/ci/delapril-delapril-manidipine-fixed-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab